Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis
Pooled result · Serum uric acid levels (paired meta-analysis)Result — go to the resultSMD −0.22 95% CI −0.42 to −0.03Authors' conclusion
SGLT-2 inhibitors significantly reduced serum uric acid levels in patients with CKD, and dapagliflozin 10 mg and ipragliflozin 50 mg may be the optimal dosages.
Study context
- Population
- Patients with chronic kidney disease (CKD); RCTs published before July 1, 2023
- Participants
- 9,367 patients8 RCTs
- Comparison
- SGLT-2 inhibitors vs placebo
- Outcome
- Serum uric acid levels
Methodological detailsBayesian framework, Grading of Recommendations, Assessment, Development and Evaluations (GRADE) certainty assessment
- Bayesian framework
- GRADE certainty assessment
Pooled result
Serum uric acid levels (paired meta-analysis)
SMD
−0.22
95% CI −0.42 to −0.03
SGLT-2 inhibitorsvs Placebo
SMD −0.22 (95% CI −0.42 to −0.03)
As reported in the abstract
Further pooled results
Serum uric acid levels by agent (subgroup analysis)
- Statistically significant difference only for tofogliflozin
Serum uric acid levels (network meta-analysis)
- Dapagliflozin 10 mg and ipragliflozin 50 mg may be the most effective in reducing uric acid levels
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Any adverse eventsGRADE: high | 0.99 (0.97–1.00) | P = 0.147 | |
| 0.512Relative risk (log scale) |
Any adverse events
- Similar incidence rates in SGLT-2 inhibitor and placebo groups
Original publication
Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis. BMJ Open Diabetes Res Care. Published 18 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →